Cyberounds Logo
September 28, 2020 | LOGIN | REGISTER | HELP | 

email a friend print Bookmark and Share
Unstable Coronary Syndromes - A Current Update
CME credit is no longer available for this conference.
Romeo A. Majano, M.D., and H. Vernon Anderson, M.D.

Dr. Marjano is Cardiology Fellow and Dr. Anderson is Professor of Medicine, University of Texas Medical.

Dr. Majano reports no commercial conflict of interest. Dr. Anderson reports no commercial conflict of interest.

Release Date: 10/18/2001
Termination Date: 10/18/2004

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe the pathophysiology underlying the unstable coronary syndromes
  • Discuss the rationale for the combination medical therapies employed for unstable coronary syndromes, the common drug agents used and their actions
  • Discuss the basic elements of clinical risk stratification in unstable coronary syndromes, and the arguments for early invasive or early noninvasive approaches.

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity